• Chlorpromazine Hydrochloride: Optimizing Antipsychotic Resea

  2026-06-15

  Chlorpromazine hydrochloride stands at the nexus of antipsychotic and antiemetic research, offering high-purity, reliable performance for dissecting dopamine receptor pathways and cell-based assays. This article spotlights advanced applications, protocol enhancements, and troubleshooting strategies—anchored by recent breakthroughs in hepatic nanoparticle interaction studies.

• NEDD4L Suppresses Colorectal Cancer Metastasis via PRMT5 Deg

  2026-06-15

  This study identifies NEDD4L as a key E3 ubiquitin ligase that prevents colorectal cancer liver metastasis by targeting PRMT5 for degradation, thereby inhibiting the AKT/mTOR pathway. These findings reveal a novel molecular mechanism with potential implications for therapeutic strategies targeting metastatic colorectal cancer.

• MG-132 (Z-LLL-al): Applied Workflows in Cancer and Apoptosis

  2026-06-14

  MG-132 (Z-LLL-al) stands out as a potent, cell-permeable proteasome inhibitor critical for apoptosis, cell cycle, and oxidative stress research. This guide presents optimized workflows, troubleshooting strategies, and actionable protocol parameters that maximize reproducibility and sensitivity in cancer and neurobiology models.

• Pandemic Response Box Screening Uncovers Novel MDR Pathogen

  2026-06-13

  This study systematically evaluated over 200 Pandemic Response Box compounds against multidrug-resistant bacterial and fungal clinical isolates, identifying several with potent in vitro activity, including candidates effective against colistin- and β-lactam-resistant strains. The findings highlight promising leads for combating challenging Gram-negative and fungal infections, and inform future antibacterial testing strategies.

• Resiniferatoxin (RTX): Catalyzing Next-Gen TRPV1 Pain Resear

  2026-06-12

  This thought-leadership article dissects the mechanistic and translational frontiers of Resiniferatoxin (RTX) as an ultra-potent TRPV1 agonist. By blending deep biological rationale, critical recent findings on lipid raft regulation, emerging models for chemical inactivation of TRPV1, and actionable protocol recommendations, it empowers translational researchers to reimagine pain model design and clinical pipelines. The narrative uniquely bridges bench-to-bedside strategy, positions RTX’s distinctiveness versus conventional agents, and elevates the conversation beyond standard product pages by illuminating new opportunities in pain and neurogenic inflammation research.

• p-Cresyl Sulfate in Endothelial Dysfunction and Calcificatio

  2026-06-12

  p-Cresyl sulfate (p-tolyl hydrogen sulfate) is transforming endothelial dysfunction and vascular calcification research by enabling precise modeling of uremia-induced cardiovascular risk. Recent protocol advancements, combined with mechanistic findings around klotho/SIRT1 signaling, position this APExBIO reagent as a cornerstone for translational CKD studies.

• Rosiglitazone (Brl-49653): Reliable PPARγ Activation for Res

  2026-06-11

  This article leverages scenario-driven analysis to address persistent laboratory challenges in metabolic, adipogenesis, and cytotoxicity assays, demonstrating how Rosiglitazone (SKU A4304) ensures reproducibility, sensitivity, and protocol compatibility. Drawing from recent literature and validated workflows, it establishes Rosiglitazone as a scientifically robust solution for researchers working on PPARγ-dependent mechanisms.

• Cyclodextrins Modulate TRPV1/TRPA1 Nociception via Cholester

  2026-06-11

  This study demonstrates that cyclodextrin derivatives suppress TRPV1 and TRPA1-mediated pain and neurogenic inflammation by depleting membrane cholesterol, offering a non-antagonist strategy for peripheral analgesia. These findings expand mechanistic understanding of ion channel regulation and suggest new avenues for pain research.

• Azilsartan Medoxomil Monopotassium: Precision Hypertension R

  2026-06-10

  Azilsartan medoxomil monopotassium (TAK 491) empowers cardiovascular and renal researchers with high-affinity, sustained AT1 receptor antagonism, optimizing both in vitro and in vivo hypertension models. This guide delivers workflow enhancements, troubleshooting insights, and evidence-driven protocol parameters to maximize reproducibility and translational impact.

• Central Pathways of Opioid-Induced Mechanical Hypersensitivi

  2026-06-10

  Yin et al. (2024) reveal a brain-to-spinal circuit controlling morphine-induced mechanical hypersensitivity and analgesic tolerance in mice. This work distinguishes the central regulation of mechanical versus thermal opioid effects and highlights new targets for mitigating opioid-induced side effects.

• Rosiglitazone (Brl-49653): Mechanistic Advances in Rare PPAR

  2026-06-09

  Explore how Rosiglitazone (Brl-49653) enables translational breakthroughs in PPARγ-linked rare diseases and advanced metabolic research. This article uncovers mechanistic insights and assay strategies distinct from standard adipogenesis workflows.

• (1S,3R)-RSL3: A Precision Tool for Ferroptosis in Cancer Bio

  2026-06-09

  (1S,3R)-RSL3 glutathione peroxidase 4 inhibitor enables precise induction of ferroptosis for advanced cancer biology research. Explore new mechanistic insights and translational strategies distinct from standard protocols.

• Chlorpromazine in Hepatic Microenvironment Assays: Beyond Tr

  2026-06-08

  Explore how chlorpromazine empowers next-generation hepatic microenvironment assays through advanced dopamine receptor signaling models. This in-depth article uniquely links antipsychotic research with nanomedicine insights for innovative experimental design.

• Marein Reverses Cancer Drug Resistance via ABCG2 Inhibition

  2026-06-08

  The reference study identifies marein, a flavonoid from Coreopsis tinctoria, as a potent and selective competitive inhibitor of the ABCG2 transporter in multidrug-resistant cancer cells. By binding a critical residue on ABCG2, marein restores chemosensitivity, offering a promising approach for overcoming drug resistance in oncology.

• Herbal Extracts Counter Danazol-Induced Precocious Puberty i

  2026-06-07

  This study demonstrates that a combined extract of Eclipta prostrata and Hordeum vulgare (EHEC) delays the onset of precocious puberty in rat models induced by danazol and high-fat diet. The findings highlight EHEC's potential as a natural modulator of the hypothalamic–pituitary–gonadal axis, offering a promising alternative for early puberty intervention.

16723 records 1/1115 page Next 12345 下5页 Last page